Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhuta, T.
Right arrow Articles by Ohlsson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhuta, T.
Right arrow Articles by Ohlsson, A.
Arch Dis Child Fetal Neonatal Ed 1998;79:F26-F33 ( July )

Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease

Tushar Bhuta, Arne Ohlsson

Shared Program in Neonatology, University of Toronto, Ontario, Canada

Correspondence to: Dr Arne Ohlsson Department of Newborn and Developmental Paediatrics Women's College Hospital 76 Grenville Street, Toronto, Ontario Canada M5G1B2. Email: aohlsson{at}globalserve.net


Accepted 26 January 1998

AIM---To review systematically the evidence to determine whether dexamethasone treatment of very low birthweight infants begun within 14 days of age prevents chronic lung disease (CLD) without clinically significant side effects.
METHODS---Randomised controlled trials of dexamethasone started within this time frame were identified through a search of electronic databases, proceedings of scientific meetings, and personal files. Meta-analyses using event rate ratio (ERR), event rate difference (ERD), and if significant, numbers needed to treat (NNT) for benefits and numbers needed to harm (NNH) for adverse effects were calculated. Weighted mean difference were used for continuous variables. Three prespecified subgroup analyses were performed for; (i) dexamethasone begun within 36 hours (hours) of birth; (ii) dexamethasone initiated between 7-14 days of age; or (iii) if surfactant treatment was used.
RESULTS---Ten studies were included in the review; six where dexamethasone was initiated within 36 hours of age, four studies for dexamethasone started between 7 and 14 days and six studies using surfactant. Mortality ERR and NNT with 95% confidence intervals for dexamethasone initiated at 7-14 days of age were 0.35 (0.16, 0.74) and 8 (4, 30). ERRs and NNTs for CLD at 28 days and 36 weeks of postmenstrual age were 0.71 (0.61, 0.84), 8 (5, 17), and 0.57 (0.44, 0.76), 10 (6, 23) in the overall analyses. When dexamethasone was started at 7 to 14 days of age ERR and NNT for CLD at 36 weeks were 0.63 (0.47, 0.85) and 3 (2, 9). Clinically significant side effects included increased risk of hypertension, hyperglycaemia, and increased time to regain birthweight.
CONCLUSIONS---These meta-analyses show a significant reduction in risk of CLD at 28 days and 36 weeks of postmenstrual age. In the subgroup where dexamethasone was started between 7 and 14 days of age mortality was significantly reduced. Caution is warranted in the routine use of dexamethasone because of lack of data on long term neurodevelopmental outcomes.

Key messages

  • Early postnatal dexamethasone begun within 14 days of age significantly reduces the risk of CLD at 28 days and 36 weeks of postmenstrual age
  • When started between 7 and 14 days of age there is also a significant reduction in mortality.
  • Significant side effects include increased risk of hypertension, hyperglycaemia, and increased time to regain birthweight
  • There are no data on long term neurodevelopmental outcomes



Keywords: dexamethasone; chronic lung disease; prevention; meta-analysis; randomised controlled trials


© 1998 by Archives of Disease in Childhood



This article has been cited by other articles:


Home page
EDUCATION AND PRACTICEHome page
S. K Sinha and S. M Donn
DIFFICULT EXTUBATION IN BABIES RECEIVING ASSISTED MECHANICAL VENTILATION
Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep42 - ep46.
[Full Text] [PDF]


Home page
PediatricsHome page
N. N. Finer, R. J. Powers, C.-h. S. Ou, D. Durand, D. Wirtschafter, J. B. Gould, and for the California Perinatal Quality Care Collabor
Prospective Evaluation of Postnatal Steroid Administration: A 1-Year Experience From the California Perinatal Quality Care Collaborative
Pediatrics, March 1, 2006; 117(3): 704 - 713.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
O Baud
Postnatal steroid treatment and brain development
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2004; 89(2): F96 - F100.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
P Ballabh, M Simm, J Kumari, A N Krauss, A Jain, C Califano, M L Lesser, and S Cunningham-Rundles
Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2004; 89(1): F76 - F83.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
E S Shinwell, M Karplus, D Bader, S Dollberg, I Gur, Z Weintraub, S Arnon, E Gottfreid, A Zaritsky, I R Makhoul, et al.
Neonatologists are using much less dexamethasone
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2003; 88(5): F432 - F433.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
G. Wang, X. Guo, and J. Floros
Human SP-A 3'-UTR variants mediate differential gene expression in basal levels and in response to dexamethasone
Am J Physiol Lung Cell Mol Physiol, May 1, 2003; 284(5): L738 - L748.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
D L Armstrong, J Penrice, F H Bloomfield, D B Knight, J A Dezoete, and J E Harding
Follow up of a randomised trial of two different courses of dexamethasone for preterm babies at risk of chronic lung disease
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2002; 86(2): F102 - F107.
[Abstract] [Full Text] [PDF]


Home page
NeoReviewsHome page
B. A. Banks
Postnatal Dexamethasone for Bronchopulmonary Dysplasia: A Systematic Review and Meta-analysis of 20 Years of Clinical Trials
NeoReviews, February 1, 2002; 3(2): e24 - 34.
[Full Text]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
M YADAV and J H BAUMER
To trigger or not to trigger?
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2000; 83(3): 224F - 224.
[Full Text]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
V Kavvadia, A Greenough, G Dimitriou, and R Hooper
Randomised trial of fluid restriction in ventilated very low birthweight infants
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2000; 83(2): 91F - 96.
[Abstract] [Full Text]


Home page
Evid. Based Nurs.Home page
D. F. Askin
A 42 day tapering course of dexamethasone reduced duration of assisted ventilation in very low birthweight infants, but increased risk of cerebral palsy at age 1 year
Evid. Based Nurs., April 1, 2000; 3(2): 41 - 41.
[Full Text]


Home page
PediatricsHome page
R. A. Sinkin, H. S. Dweck, M. J. Horgan, K. J. Gallaher, C. Cox, W. M. Maniscalco, P. R. Chess, C. T. D'Angio, R. Guillet, J. W. Kendig, et al.
Early Dexamethasone---Attempting To Prevent Chronic Lung Disease
Pediatrics, March 1, 2000; 105(3): 542 - 548.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health